Molecular Partners AG ADR share price logo

Molecular Partners AG ADR Share Price

NASDAQ: MOLN

Small Cap

$4.40

+0.06

(+1.38%)

Live

as on

Molecular Partners AG ADR Stock Performance

as on April 25, 2026 at 2:09 am IST

  • Day's High

    $4.40
    $4.47

    1.59%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.36
    $5.36
    downward going graph

    23.64%

    Downside

    21.82%

    Upside

    downward going graph

Molecular Partners AG ADR share price movements today

Previous Close
$4.34
Open
$4.40
Volume
46.7K
Day's Low - High
$4.40 - $4.47
52 Week Low - High
$3.36 - $5.36

Molecular Partners AG ADR Historical Returns

1 Month Return
+ 1.15 %
3 Month Return
+ 7.58 %
1 Year Return
+ 7.84 %
3 Year Return
-33.43 %
5 Year Return
0 %

Molecular Partners AG ADR Stock Fundamentals & Key Indicators

Check Molecular Partners AG ADR market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$162.4M

EPS (TTM)

-1.1173

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-54.5M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-55.55%

Molecular Partners AG ADR vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Molecular Partners AG ADR with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Molecular Partners AG ADR image
Molecular Partners AG ADR
SELL$162.4MNANA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.4B129.51%133.38.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.3B99.68%28.5732.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.3BNA121.875.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.9B56.77%17.9931.41%

Stock Returns calculator for Molecular Partners AG ADR Stock including INR - Dollar returns

The Molecular Partners AG ADR stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Molecular Partners AG ADR investment value today

Current value as on today

₹1,19,095

Returns

₹19,095

(+19.1%)

Returns from Molecular Partners AG ADR Stock

₹7,843 (+7.84%)

Dollar Impact

₹11,252 (+11.25%)

Analyst Recommendation on Molecular Partners AG ADR Stock

Based on 11 analysts

SELL

9.09%

Buy

27.27%

Hold

63.64%

Sell

Based on 11 analysts, 63.64% of analysts recommend a 'SELL' rating for Molecular Partners AG ADR. Average target price of $11.18

Molecular Partners AG ADR Share Price Target

Get share price movements and forecasts by analysts on Molecular Partners AG ADR.

What analysts predicted

60.64%UPSIDE

Target Price

$11.18

Current Price

$4.4

Analyzed by

11 Analysts

Target

$11.18

Molecular Partners AG ADR target price $11.18, a slight upside of 60.64% compared to current price of $4.4. According to 11 analysts rating.

Molecular Partners AG ADR Stock’s Investor Sentiment and Interest

Search interest for Molecular Partners AG ADR Stock has increased by 50% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:50% versus previous 30 day period

Molecular Partners AG ADR Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
2
1
3
1
0
-
-
-
-
-
Gross Profit
-10
-12
-12
-12
-12
-10
-13
-10
-8
0
Operating Income
-13
-16
-15
-15
-14
-14
-16
-17
-12
-12
EBITDA
-10
-19
-10
-14
-15
-10
-16
-19
-11
-12
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-19
-11
-15
-16
-11
-16
-20
-11
-12
Income Tax Expense
0
0
0
-
-
0
0
-
-
0
Net Income
-12
-22
-12
-16
-19
-12
-18
-20
-11
-12
Net Profit Margin
-450.18%
-1916.67%
-413.62%
-972.40%
-2408.81%
0.00%
0.00%
0.00%
0.00%
0.00%

Molecular Partners AG ADR Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
22
20
10
20
10
10
203
8
5
-
Gross Profit
8
2
-5
-23
-52
-50
148
-47
-47
-
Operating Income
-19
-25
-37
-36
-58
-63
116
-61
-61
-58
EBITDA
-17
-24
-36
-33
-59
-60
119
-59
-51
-59
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
-
1
0
2
2
2
2
2
2
2
Income Before Tax
-18
-25
-37
-36
-62
-63
117
-61
-54
-61
Income Tax Expense
0
0
0
0
0
0
0
2
0
0
Net Income
-18
-25
-37
-36
-70
-69
126
-71
-60
-61
Net Profit Margin
-80.78%
-127.05%
-357.66%
-178.03%
-671.70%
-683.65%
62.17%
-880.70%
-1087.38%
0.00%

Molecular Partners AG ADR Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-19
-11
-15
-16
-11
-16
-20
-11
-12
Operating Cash Flow
-15
-17
-15
-13
-13
-17
-13
-9
-10
Investing Cash Flow
19
17
13
14
-4
34
14
10
11
Financing Cash Flow
0
0
0
0
15
0
0
0
0
Change in Cash
-1
1
-4
0
-1
17
0
0
0

Molecular Partners AG ADR Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-25
-37
-36
-62
-63
117
-61
-54
-61
Operating Cash Flow
-40
-42
-1
-28
-90
118
-59
-59
-51
Investing Cash Flow
20
9
-19
-21
-22
-101
44
40
72
Financing Cash Flow
0
0
0
113
50
-1
-1
14
-1
Change in Cash
-18
-32
-23
58
-61
16
-20
-3
18

Global Institutional Holdings in Molecular Partners AG ADR

Funds
Holdings
UBS Group AG
0.01%
Morgan Stanley - Brokerage Accounts
0%
EverSource Wealth Advisors, LLC
0%
Bank of America Corp
0%
EverSource Wealth Advisors, LLC
0%
See all

Molecular Partners AG ADR News & Key Events

  • img

    Today's Timeline - 12 November

    Wed, 04:22 PM

    -

    Molecular Partners presents new data on MP0712, highlighting first human images and supporting mechanism of action for small cell lung cancer treatment.

Insights on Molecular Partners AG ADR

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, MOLN stock has moved up by 4.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 29.3% return, outperforming this stock by 21.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 53.2% return, outperforming this stock by 86.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -11.83M → -12.64M (in $), with an average decrease of 6.9% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 2.73M → 681.0K (in $), with an average decrease of 49.7% per quarter

About Molecular Partners AG ADR

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
OrganisationMolecular Partners AG ADR
HeadquartersWagistrasse 14, Schlieren, Switzerland, 8952
IndustryBiotechnology
CEODr. Patrick Amstutz Ph.D.
E-voting on sharesClick here to vote

Key Management of Molecular Partners AG ADR

Name

Title

Mr. Robert Hendriks

Senior VP of Finance & Member of Management Board

Mr. Alexander Zurcher

COO & Member of Management Board

Mr. Daniel Steiner Ph.D.

Senior Vice President of Research & Technology

Mr. Michael Pitzner

Executive VP of Partnering & General Counsel

Dr. Patrick Amstutz Ph.D.

Co-Founder, CEO, Member of Management Board & Director

Dr. Michael Tobias Stumpp Ph.D.

Co-Founder, Executive VP of Projects & Member of Management Board

Ms. Renate Gloggner

Executive VP of People & Community and Member of Management Board

Dr. Philippe Legenne M.B.A., M.D.

Chief Medical Officer & Member of the Management Board

Mr. Martin Steegmaier Ph.D.

Chief Scientific Officer & Member of the Management Board

Dr. Pamela A. Trail Ph.D.

Strategic Consultant

FAQs

What is Molecular Partners AG ADR share price today?

Molecular Partners AG ADR share price today is $4.4 as on . Molecular Partners AG ADR share today touched a day high of $4.47 and a low of $4.4.

What is the 52 week high and 52 week low for Molecular Partners AG ADR share?

Molecular Partners AG ADR share touched a 52 week high of $5.36 on and a 52 week low of $3.36 on . Molecular Partners AG ADR stock price today i.e. is trending at $4.4,which is 17.91% down from its 52 week high and 30.95% up from its 52 week low.

What is Molecular Partners AG ADR's market capitalisation today?

Molecular Partners AG ADR market capitalisation is $0.00T as on .

How to invest in Molecular Partners AG ADR Stock (MOLN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Molecular Partners AG ADR on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Molecular Partners AG ADR Shares that will get you 0.3409 shares as per Molecular Partners AG ADR share price of $4.4 per share as on April 24, 2026 at 8:39 pm IST.

What is the minimum amount required to buy Molecular Partners AG ADR Stock (MOLN) from India?

Indian investors can start investing in Molecular Partners AG ADR (MOLN) shares with as little as ₹94.228 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹942.28 in Molecular Partners AG ADR stock (as per the Rupee-Dollar exchange rate as on ). Based on Molecular Partners AG ADR share’s latest price of $4.4 as on April 24, 2026 at 8:39 pm IST, you will get 2.2727 shares of Molecular Partners AG ADR. Learn more about fractional shares .